Guizhou Medical University
14
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
14.3%
2 terminated/withdrawn out of 14 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer
Role: lead
Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
Role: lead
Intervention Program for Alarm Fatigue in NICU Nurses Based on ABC-X Model
Role: lead
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
Role: collaborator
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
Role: collaborator
A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease
Role: collaborator
Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study
Role: lead
Folic Acid Interferes With Radiation Esophagitis
Role: lead
Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer
Role: lead
Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC
Role: lead
A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC
Role: lead
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC
Role: lead
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
Role: lead
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
Role: lead
All 14 trials loaded